Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1974 1
1977 1
1980 1
1981 5
1982 6
1983 9
1984 7
1985 2
1986 3
1987 4
1988 12
1989 14
1990 12
1991 11
1992 10
1993 6
1994 10
1995 7
1996 16
1997 8
1998 14
1999 14
2000 11
2001 7
2002 9
2003 8
2004 7
2005 12
2006 9
2007 8
2008 9
2009 9
2010 4
2011 11
2012 12
2013 11
2014 6
2015 5
2016 7
2017 16
2018 7
2019 8
2020 11
2021 13
2022 9
2023 5
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

366 results

Results by year

Filters applied: . Clear all
Page 1
Nasal High Flow Therapy for Bronchiolitis.
Franklin D, Miller L, Pham TM, Frampton C, Moloney S, Waugh J, Fairless S, Hobbins S, Grew S, George S, Fahy R, Morel D, Schibler A. Franklin D, et al. Among authors: morel d. J Paediatr Child Health. 2024 May 22. doi: 10.1111/jpc.16557. Online ahead of print. J Paediatr Child Health. 2024. PMID: 38775344
LymphoDose: a lymphocyte dose estimation framework-application to brain radiotherapy.
de Kermenguy F, Benzazon N, Maury P, Vauclin R, M'hamdi M, Cifliku V, Limkin E, Diallo I, Morel D, Milewski C, Clémenson C, Mondini M, Deutsch E, Robert C. de Kermenguy F, et al. Among authors: morel d. Phys Med Biol. 2024 Apr 29;69(10). doi: 10.1088/1361-6560/ad3c8d. Phys Med Biol. 2024. PMID: 38593817
Enhancing radioprotection: A chitosan-based chelating polymer is a versatile radioprotective agent for prophylactic and therapeutic interventions against radionuclide contamination.
Durand A, Borisova T, Lux F, Howard JA, Tillement A, Kuznietsova H, Dziubenko N, Lysenko V, David L, Morel D, Berbeco R, Komisarenko S, Tillement O, Deutsch E. Durand A, et al. Among authors: morel d. PLoS One. 2024 Apr 3;19(4):e0292414. doi: 10.1371/journal.pone.0292414. eCollection 2024. PLoS One. 2024. PMID: 38568898 Free PMC article.
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. Levy A, et al. Among authors: morel d. Mol Cancer. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8. Mol Cancer. 2024. PMID: 38519913 Free PMC article. Clinical Trial.
KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner.
Laurent PA, Milic M, Quevrin C, Meziani L, Liu W, Morel D, Signolle N, Clémenson C, Levy A, Mondini M, Deutsch E. Laurent PA, et al. Among authors: morel d. J Transl Med. 2023 Oct 31;21(1):773. doi: 10.1186/s12967-023-04619-0. J Transl Med. 2023. PMID: 37907934 Free PMC article.
366 results